A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention by 怨좎쁺援� & 源�蹂묎레
Yonsei Med J   http://www.eymj.org   Volume 52   Number 5   September 2011 717
Original Article http://dx.doi.org/10.3349/ymj.2011.52.5.717pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 52(5):717-726, 2011
A Randomized Study Assessing the Effects of  Pretreatment  
with Cilostazol on Periprocedural Myonecrosis  
after Percutaneous Coronary Intervention
Byeong-Keuk Kim,1, 2 Seung Jin Oh,1 Se-Jung Yoon,1 Dong Woon Jeon,1 
Young-Guk Ko,2 and Joo Young Yang1
1Cardiology Division, Cardiovascular Center of National Health Insurance Corporation Ilsan Hospital, Goyang;
2Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seoul, Korea.
Received: October 11, 2010
Revised: November 28, 2010
Accepted: November 29, 2010
Corresponding author: Dr. Joo Young Yang,
Cardiology Division, Cardiovascular Center of 
the National Health Insurance Corporation 
Ilsan Hospital, 1232 Baekseok 1-dong, 
Ilsandong-gu, Goyang 410-719, Korea.
Tel: 82-31-900-3164, Fax: 82-31-900-0343
E-mail: kbk2565@freechal.com 
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2011
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: It is unknown whether cilostazol pretreatment reduces postprocedural 
myonecrosis (PPMN). Cilostazol pretreatment reduces PPMN after percutaneous 
coronary intervention (PCI). Materials and Methods: A total of 120 patients with 
stable angina scheduled for elective PCI were randomly assigned to a 7-day pre-
treatment with Cilostazol (200 mg/day) or to a control group. Creatine kinase-MB 
(CK-MB) and cardiac troponin I (cTnI) levels were measured at baseline and at 6 
and 24 hours after PCI. The primary end-point was the occurrence of PPMN, de-
fined as any CK-MB elevation above the upper normal limit (UNL). Aspirin and 
clopidogrel were co-administered for 7 days before PCI, and resistance to these 
agents was then assayed using the VerifyNow System. Results: There was no dif-
ference in baseline characteristics between the final analyzable cilostazol (n=54) 
and the control group (n=56). Despite a significantly greater % inhibition of clopi-
dogrel in the cilostazol group (39±23% versus 25±22%, p=0.003), the incidence of 
PPMN was similar between the cilostazol group (24%) and the control group 
(25%, p=1.000). The rate of CK-MB elevation at ≥3 times UNL was also similar 
between the two groups (6% versus 5%, p=0.583). The incidence of cTnI increase 
over the UNL or to 3 times the UNL was not different between the two groups. 
There was no significant difference in terms of the rate of adverse events during fol-
low-up, although the cilostazol group showed a tendency to have a slightly higher 
incidence of entry site hematoma. Conclusion: This trial demonstrated that ad-
junctive cilostazol pretreatment might not significantly reduce PPMN after elec-
tive PCI in patients with stable angina.
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INTRODUCTION
   
Periprocedural myocardial injury, as assessed by creatine kinase-MB (CK-MB) el-
evation, is a frequent complication of percutaneous coronary intervention (PCI), 
occurring in up to 40-45% of cases.1-3 An increase in CK-MB after PCI is associat-
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lesion length (≥28 or <28 mm). Inclusion criteria were sta-
ble angina with the presence of typical angina or positive 
stress test (electrocardiogram, treadmill test, or nuclear scan) 
and indications for stent implantation. Exclusion criteria 
were: any increase in CK-MB or cardiac troponin I (cTnI); 
acute myocardial infarction (MI) (<3 months); any increase 
in liver enzyme [aspartate aminotransferase (AST)/alanine 
aminotransferase (ALT)]; left ventricle ejection fraction 
<30%; renal failure with creatinine >3 mg/dL; history of 
liver or muscle disease; coronary lesions with left main dis-
ease, chronic total occlusion, in-stent restenosis, or bare-
metal stent (BMS) implantation; current therapy with 
statins (for the exclusion of the effects of pretreatment with 
various statins); or needing PCI within 7 days of diagnostic 
coronary angiography. After undergoing diagnostic coro-
nary angiography using radial artery access at an out-patient 
clinic, patients fulfilling the criteria were randomly assigned 
to each group. Randomization was stratified according to age 
(<65 or ≥65 years), presence of bifurcation lesions, and le-
sion length (<28 or ≥28 mm), which were regarded as the 
important predictors for periprocedural myonecrosis.3,4 Clini-
cal follow-up of enrolled patients was performed for 6 
months. The local ethics committee approved the study, and 
all patients gave written informed consent. 
   
Percutaneous coronary intervention procedure
Stents were implanted according to current clinical practice 
guidelines. Angiographic success was defined as final angi-
ographic residual stenosis of <20% by quantitative coro-
nary angiographic analysis. All patients received daily aspi-
rin 100-200 mg and clopidogrel 75 mg starting from 7 days 
before the elective PCI. Before PCI, all patients received a 
60 IU/kg intravenous bolus of unfractionated heparin. Gly-
ed with higher mortality during follow-up.3,4 Moreover, it 
has been reported that even a mild postprocedural elevation 
of CK-MB can influence the mortality rate.4 Although many 
strategies have been proposed for reducing periprocedural 
myocardial injury after PCI,2,3,5,6 to date, there have been no 
studies evaluating the effectiveness of pre-treatment with 
cilostazol, a potent type III phosphodiesterase inhibitor, 
which is already well-known for its various benefits, such 
as antiplatelet and antithrombotic effects, vasodilating prop-
erties, reductions in clopidogrel resistance, and other pleio-
tropic actions.7-9
Therefore, we designed a prospective randomized study 
to assess whether pretreatment with cilostazol before PCI in 
patients with stable angina could reduce periprocedural 
myonecrosis,10 which was defined as any CK-MB elevation 
above the upper normal limit (UNL) after PCI.
MATERIALS AND METHODS
　　　
Patients and study design
The study design is shown in Fig. 1. The CiLostazol ad-
ministration before pErcutaneous coronAry intervention for 
Reduction of periprocedural myonecrosis trial (CLEAR tri-
al) was a single center, randomized, prospective trial. Be-
tween June 2007 and May 2009, patients with typical angi-
na, not taking statins and without elevated levels of cardiac 
enzymes, who were scheduled for drug-eluting stent (DES) 
implantation in de novo coronary artery lesions were ran-
domly assigned 1 : 1 to pretreatment with cilostazol 200 
mg/day for 7 days (Cilostazol group) or to no pretreatment 
(control). Stratified randomization was performed accord-
ing to age (≥65 or <65 years), presence of bifurcation, and 
Fig. 1. Study design and summary. PCI, percutaneous coronary intervention.
Typical angina; elective PCI after 7 day-pretreatment (n=120)
Cilostazol group (200 mg/d×7 days)
(n=60)
Control group (n=60)
#4 patient excluded
-Non-available cardiac enzyme (n=2)
-Withdrawal of agreement (n=2)
#6 patient excluded
-Non-available cardiac enzyme (n=4)
-Withdrawal of agreement (n=2)
Cilostazol group (n=54) Control group (n=56)
Detection of periprocedural myocardial injury; check cardiac enzyme at 6-8 hours, and 24 hours later
Elective PCI after 7-day pre-treatment according to the groups
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elevation above the UNL, 3 times, or 10 times above the 
UNL after PCI; 4) comparison of the rate of periprocedural 
myonecrosis according to the presence of clopidogrel resis-
tance; and 5) rate of in-hospital and 6-month adverse events 
such as major adverse cardiac events (MACE; death, acute 
MI, need for bypass surgery or repeat PCI), stent thrombo-
sis, cerebrovascular accidents (CVA), bleeding, or other se-
rious side effects.
Bleeding was defined based on the Global Utilization of 
Streptokinase and Tissue Plasminogen Activator for Oc-
cluded Coronary Arteries bleeding classification: severe or 
life-threatening bleeding was defined as intracerebral bleed-
ing or bleeding with substantial hemodynamic compromise 
requiring treatment. Moderate bleeding was defined by the 
need for transfusion. Minor bleeding referred to other bleed-
ing, not requiring transfusion or causing hemodynamic 
compromise.12 Bleeding at the percutaneous entry site was 
defined by the size of external hematoma (>10 cm for fem-
oral and >2 cm for radial access) during or after the cathe-
terization laboratory visit until discharge.13
  
Statistical analysis
According to recent studies, loading of clopidogrel before 
PCI reduced the occurrence of postprocedural ischemic com-
plications by 45%.5,14 Assuming that the cilostazol pretreat-
ment would be as potent as or more potent than high dose 
clopidogrel loading in the reduction of periprocedural myo-
necrosis and that the incidence of periprocedural myonecro-
sis of the control group would be 40-45%, we could expect 
the incidence of periprocedural myonecrosis to be 15% in the 
trial group. Thus, a sample size of 110 patients (55 patients in 
each group) would provide 80% power to detect a difference 
with an alpha (probability value) of 0.05. Based on a with-
drawal rate of about 10%, sixty patients per each group, i.e., 
a total of 120 patients, were considered appropriate. 
Statistical analysis was performed with Statistical Package 
for the Social Sciences (SPSS) software (SPSS Inc., Chica-
go, IL, USA). Categorical data, presented as numbers with 
frequencies, were compared with chi-square statistics or 
Fisher’s exact test, while continuous data, presented as 
mean±SD, were compared with Student’s t-test for normally 
distributed values; otherwise, the Mann Whitney U test was 
applied. To determine the independent predictors for peripro-
cedural myonecrosis, multivariate logistic regression analysis 
was performed, and variables that were predictive at the 0.1 
level by univariate analysis were entered into final multivari-
ate analysis. A value of p<0.05 denoted significance.
coprotein IIb/IIIa inhibitors were administered according to 
the operatorʼs discretion. Angiographic analysis was per-
formed with a computer-assisted automated edge-detection 
algorithm (Phillip INTEGRIS BH 5,000, Phillips Medical 
Systems, the Netherlands). Angiographic complications in-
cluded: side branch occlusions (transient or permanent); 
abrupt intra-procedural vessel closure; major or minor dis-
section; thrombus formation; transient and/or prolonged 
slow-no reflow; and distal embolization. All patients re-
ceived clopidogrel 75 mg/day for at least 6 months in addi-
tion to continued aspirin (100 mg/day).
Laboratory measurements 
Venous blood samples were drawn immediately after ran-
domization (baseline), before (7 days later after pre-treat-
ment), and 6 and 24 hours after PCI. CK-MB and cTnI lev-
els were determined using a radioimmunoassay analyzer 
(Dimension RxL Analyzer; Dade Behring, Marburg, Ger-
many). The UNL, which represents the 99th percentile of 
the distribution of a reference control group with an analyti-
cal imprecision of more than 10%, was 4 ng/mL for CK-
MB and 0.2 ng/mL for cTnI. The peak enzyme ratio was 
calculated as the level of peak cardiac enzyme divided by 
the value of the upper normal limit. Before discharging the 
patients, we performed aspirin and clopidogrel resistance 
testing using the VerifyNow-ASA and -P2Y12TM assays 
(Accumetrics Inc., San Diego, CA, USA). Samples were 
obtained by antecubital venipunture using a 23-gauge sy-
ringe, and the initial 3 to 4 mm of blood was discarded. The 
second samples were collected in 4.5-mL plastic tubes con-
taining 3.2% citrate for rapid platelet-function assay.8 The 
results of the aspirin and clopidogrel resistance tests were 
expressed as aspirin reaction unit (ARU) and percentage in-
hibition rate, respectively.8,11 The percentage inhibition of 
clopidogrel was calculated as (1- P2Y12 reaction unit/ esti-
mated baseline) ×100. Aspirin resistance was defined as an 
ARU of ≥550, and clopidogrel resistance as percentage inhi-
bition of clopidogrel <20%.8
  
Study end points
The primary end point was the occurrence of periprocedur-
al myonecrosis, defined as any CK-MB elevation above the 
UNL.10 Secondary end points included: 1) the occurrence 
of periprocedural MI, defined as a postprocedural increase 
in CK-MB level ≥3 times above the UNL; 2) the occur-
rence of a large periprocedural MI, defined as a postproce-
dural increase of CK-MB ≥10 times above the UNL; 3) cTnI 
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stazol group (n=54)] versus [control group (n=56)] (Fig. 1). 
There were no significant differences in baseline clinical 
and biochemical variables between the two groups (Table 
1). The angiographic and procedural characteristics were 
similar between the two groups (Table 2 and 3). The occur-
rence of angiographic complications during the procedure 
RESULTS
 
Baseline clinical and angiographic data
Among all the enrolled patients, 10 were excluded, and the 
remaining 110 were ultimately eligible for our study; [cilo-
Table 1. Clinical Characteristics of the Patients Enrolled in the Two Groups
Variable Cilostazol (n=54) Control (n=56) p value
Age (yrs) 64±9 67±9 0.131
Men, n (%) 28 (52) 25 (45) 0.449
Hypertension, n (%) 37 (69) 38 (68) 0.941
Active smokers, n (%)   8 (15)   7 (13) 0.752
Diabetes, n (%) 21 (39) 25 (45) 0.541
Hyperlipidemia, n (%)   9 (17) 15 (27) 0.189
Previous stroke, n (%) 1 (2) 2 (4) 1.000
Previous myocardial infarction, n (%)    1 (2%)    1 (2%) 1.000
Previous coronary intervention, n (%) 2 (4) 4 (7) 0.679
Previous bypass surgery, n (%) 0 (0) 0 (0) 1.000
Left ventricular ejection fraction (%) 66±6 65±7 0.404
Medications
    Aspirin, n (%)   54 (100)   56 (100) 1.000
    Clopidogrel, n (%) 53 (98)   56 (100) 0.439
    β-Blockers, n (%) 34 (63) 31 (55) 0.417
    ACE inhibitors or ARB, n (%) 35 (65) 43 (77) 0.167
Laboratory test before randomization
    WBC (/μL)   6,931±1,822   6,647±1,950 0.446
    hs-CRP (mg/dL)   0.29±0.36   0.26±0.53 0.740
    Blood urea nitrogen (mg/dL) 12±5 13±4 0.089
    Serum creatinine (mg/dL)   0.9±0.4   0.9±0.2 0.317
    AST (IU/L) 22±7   25±14 0.132
    ALT (IU/L)   21±10 21±9 0.898
Values are mean±SD or numbers (percentages). 
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; hs-CRP, high-sensitive C-reactive protein; WBC, white blood cell; 
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 2. Angiographic Characteristics
Variable Cilostazol (n=54) Control (n=56) p value
Numbers of lesions treated 70 79
Vessel treated, Left anterior descending, n (%) 38 (54) 43 (55) 0.994
Number of diseased vessels 0.460
    1, n (%) 28 (52) 22 (41)
    2, n (%) 14 (26) 20 (36)
    3, n (%) 12 (22) 14 (25)
Lesion type B2/C, n (%) 41 (59) 41 (52) 0.559
Bifurcation, n (%) 22 (31) 16 (20) 0.075
Reference vessel diameter (mm)
    Pre 2.74±0.36 2.76±0.39 0.743
    Post 2.88±0.37 2.90±0.40 0.739
Minimal lumen diameter (mm)
    Pre 0.80±0.31 0.84±0.33 0.462
    Post 2.69±0.38 2.67±0.44 0.759
Lesion length (mm) 21.6±8.2 22.3±7.8 0.591
Values are mean±SD or numbers (percentages). 
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defined by % inhibition of <20%, was significantly lower in 
the cilostazol group [12 patient (22%)] than in the control 
group [27 patients (48%), p=0.006] (Fig. 2C), which means 
the cilostazol group had significantly reduced clopidogrel re-
sistance. 
  
Postprocedural cardiac enzyme increases
Periprocedural myonecrosis, defined as any postprocedural 
increase in CK-MB above the UNL, was detected in 13 
was similar between the two groups (Table 3). 
  
Aspirin and clopidogrel resistance after pretreatment 
After 7 days of pretreatment, there was no significant differ-
ence in ARU between the cilostazol and control groups 
(418±71 versus 435±46, p=0.170) (Fig. 2A). However, the % 
inhibition of clopidogrel was significantly higher in the cilo-
stazol group (39±23%) than in the control group (25±22%, 
p=0.003) (Fig. 2B). The prevalence of clopidogrel resistance, 
Table 3. Procedural Characteristics
Variable Cilostazol (n=54) Control (n=56) p value
Type of stent 0.723
    Sirolimus-eluting stent, n (%) 35 (50)  44 (56)
    Paclitaxel-eluting stent, n (%)   8 (11)    9 (11)
    Zotarolimus-eluting stent, n (%)  15 (22)  16 (20)
    Everolimus-eluting stent, n (%)    7 (10)  6 (8)
    Others, n (%)  5 (7)  4 (5)
Angiographic success, n (%)    54 (100)    56 (100) 1.000
Multi-vessel coronary intervention, n (%)  11 (20) 17 (30) 0.200
Stent diameter (mm) 2.97±0.39  2.96±0.38 0.821
Total stened length (mm) 25.7±10.7  28.4±12.1 0.145
Multiple overlapping stents, n (%)    7 (10)  12 (15) 0.465
Direct stenting, n (%)  14 (20)  11 (14) 0.236
Duration of stent deployment (seconds) 11±3 11±4 0.896
Maximum pressure inflation (atm) 15±3 16±3 0.515
Use of postdilation, n (%)  66 (94)  75 (95) 1.000
Use of IIb/IIIa inhibitors, n (%)  0 (0)  0 (0) 1.000
Angiographic complications
    Major dissection, n (%)  1 (2)  0 (0) 0.495
    Abrupt closure, n (%)  0 (0)  0 (0) 1.000
    Slow/No reflow, n (%)  0 (0)  1 (2) 1.000
    Thrombus formation, n (%)  0 (0)  0 (0) 1.000
    Distal embolization, n (%)  0 (0)  0 (0) 1.000
    Side-branch occlusion, n (%)  0 (0)  0 (0) 1.000
Values are mean±SD or numbers (percentages). 
Fig. 2. Antiplatelet responsiveness in the two study arms. Comparison of Aspirin Resistance unit (A), percentage of inhibition of clopido-
grel (B), and the incidence of clopidogrel resistance (C) between the two groups.
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significant independent predictor for any CK-MB elevation 
was the presence of multivessel disease [odds ratio (OR) 
=4.25, 95% confidence interval (CI) 1.49-10.09, p=0.010)]. 
However, cilostazol pretreatment was not a significant pre-
dictor (OR=0.92, 95% CI 0.36-2.40, p=0.814) (Table 4).
  
Adverse events during hospital stay and 6-month 
follow-up period 
Both in the hospital and during the 6 months of follow-up, 
there was no significant difference in the occurrence of fatal 
(24%) patients in the cilostazol group and in 14 (25%) in 
control group, showing similar rates (p=1.000) (Fig. 3A). 
The incidences of periprocedural MI (CK-MB ≥3 times) or 
large periprocedural MI (≥10 times UNL) were not signifi-
cantly different between the two groups. cTnI elevation 
above the UNL or ≥3 or 10 times above the UNL occurred at 
a similar rate between the two groups (Fig. 3B). In addition, 
there were no differences in the level of peak or peak ratio 
of CK-MB or cTnI after PCI (Fig. 4). 
Using multivariate logistic regression analysis, the most 
Table 4. Multivariate Predictors for the Occurrence of Periprocedural Myonecrosis
Odds ratio 95% confidence interval p value
Age 1.01 0.95-1.07 0.822
Diabetes 3.35   1.28-15.91 0.040
Cilostazol pretreatment 0.77 0.28-2.15 0.623
Baseline hs-CRP 1.00 0.99-1.01 0.782
Multi-vessel diseases 4.25   1.49-10.09 0.010
Complex lesions 2.17 0.62-7.63 0.226
Multi-vessel PCI 1.67 0.53-5.22 0.382
hs-CRP, high-sensitive C-reactive protein; PCI, percutaneous coronary intervention.
Fig. 3. Comparison of postprocedural creatine kinase MB (CK-MB) and cardiac troponin I (cTnI) elevation in the two study groups. The 
combined areas of the boxes in three different colors (white, black, and gray) indicate the proportion of patients with any CK-MB (24% in 
cilostazol group and 25% in control) (A) or cTnI (33% in cilstazol group and 39% in control) (B) elevation above the upper normal limit.
Fig. 4. Comparison of the postprocedural peak value and the peak ratio of creatine kinase MB (CK-MB) (A) and cardiac troponin I (cTnI) 
(B) between the cilostazol and control groups. Peak enzyme ratio was calculated as peak cardiac enzyme divided by the value of the up-
per normal limit.
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times above the UNL between the two groups, respectively. 
The level of peak CK-MB or cTnI of the patients with clopi-
dogrel resistance was not significantly different from those 
of the patients with normal response to clopidogrel (peak 
CK-MB; 5.4±19.7 vs. 5.1±10.1 ng/mL, p=0.904, peak cTnI; 
0.7±3.1 vs. 0.7±2.5 ng/mL, p=0.910). The composite inci-
dence of cardiac death, MI, target-lesion revascularization, 
or CVA in patients with clopidogrel resistance was slightly 
higher than that of patients with normal responses to the 
clopidogrel, but the difference did not achieve statistical 
significance (Table 6).
DISCUSSION
   
This randomized CLEAR trial demonstrates that pretreat-
ment with cilostazol 200 mg/d for 7 days did not significant-
ly reduce the rate of periprocedural myonecrosis, defined as 
any elevation of CK-MB after elective PCI, in patients with 
stable angina, despite a reduction of clopidogrel resistance 
by cilostazol. 
Increases in postprocedural cardiac enzyme could be re-
lated with multiple factors, such as: 1) procedure-related 
complications; 2) lesion-specific characteristics; 3) platelet 
activity related with micro-embolization; 4) arterial inflam-
mation; 5) antiplatelet resistance; and 6) genetic predisposi-
events (Table 5). The occurrence of bleeding events was not 
significantly different between the two groups. However, 
the cilostazol group showed a tendency toward a slightly 
higher rate of any bleeding, chiefly due to the high incidence 
of entry site hematoma. Closure devices were used for all 
enrolled patients and the proportions of use of various types 
did not differ between the groups. There were no cases with 
retroperitoneal bleeding or requiring further intervention to 
control bleeding. All entry site hematomas spontaneously 
resolved before discharge. In addition, there was no rela-
tionship between bleeding episodes, including major and 
minor bleeding, and those resultant clinical outcomes. 
    
Relationship between clopidogrel resistance, 
postprocedural cardiac enzyme increases and follow-up 
clinical outcomes
To evaluate the effects of clopidogrel resistance on postpro-
cedural enzyme level increases and clinical outcomes, we 
divided patients into two groups based on the value of % 
inhibition of clopidogrel: patients with clopidogrel resis-
tance (% inhibition <20) [n=37 (34%)] and patients with 
normal response to clopidogrel (% inhibition ≥20) [n=73 
(66%)] (Table 6). The incidences of any CK-MB or cTnI 
elevation were not different between the two groups. In ad-
dition, there were no significant differences in the incidence 
of postprocedural CK-MB or cTnI level ≥3 times or 10 
Table 5. Adverse Events during In-Hospital and 6-Month Follow-Up
Variable Cilostazol (n=54) Control (n=56) p value
In-hospital events
    Cardiac death, MI, or TLR, n (%) 0 (0) 0 (0) 1.000
    CVA, n (%) 0 (0) 1 (2) 1.000
6-month cumulative events
    Death, cardiac, n (%) 0 (0) 1 (2) 1.000
    MI, n (%) 0 (0) 1 (2) 1.000
    TLR, n (%) 1 (2) 2 (4) 0.698
    Non-TLR, n (%) 0 (0) 0 (0) 1.000
    CVA, n (%) 0 (0) 1 (2) 1.000
    Death, MI, or TLR, n (%) 1 (2) 4 (7) 0.364
    Death, MI, TLR, or CVA, n (%) 1 (2) 5 (9) 0.206
    Stent thrombosis, n (%) 0 (0) 2 (4) 0.241
Drug discontinuation due to side effects, n (%) 0 (0) 0 (0) 1.000
Bleeding events by GUSTO classification
    Severe, n (%) 2 (4) 0 (0) 0.146
    Moderate, n (%) 0 (0) 0 (0) 1.000
    Mild, n (%)   9 (17) 5 (9) 0.190
    Any bleeding, n (%) 11 (20) 5 (9) 0.089
Entry site hematoma, n (%)   9 (17) 4 (7) 0.223
Values are mean±SD or numbers (percentages).
MI, myocardial infarction; TLR, target-lesion revascularization; CVA, cerebrovascular accidents; non-TLR, non-target lesion revascularization.
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dogrel resistance has been known to affect the incidence of 
adverse outcomes following stent implantation.11,18,19 Howev-
er, a non-randomized study by Buch, et al.18 found no cor-
relation between aspirin or clopidogrel resistance and myo-
necrosis. Similarly, our randomized trial demonstrated that 
there was no significant relationship between clopidogrel 
resistance and the incidence of periprocedural myonecrosis, 
despite the lower rate of clopidogrel resistance by cilostazol 
pretreatment. This finding suggests that clopidogrel resis-
tance may not contribute as much to the occurrence of post-
procedural myocardial injury as other important factors. 
However, as this CLEAR trial was not designed for the de-
termination of the role of clopidogrel resistance on peripro-
cedural myonecrosis, further investigation is warranted. In 
addition, patients with acute coronary syndrome were ini-
tially excluded in this study. Therefore, for the definite es-
tablishment of the role of cilostazol in the prevention of 
periprocedural myocardial infarction, a study including pa-
tients with acute coronary syndrome will be necessary in 
the future. 
The surprisingly low incidence of CK-MB elevation in 
the control group could underlie the negative results in the 
CLEAR trial. The incidence of any CK-MB elevation in 
the control group was 25%, and that of CK-MB elevation 
≥3 times the UNL was only 6%. This low incidence might 
be explained by the more stable characteristics of the en-
rolled patients or lesions, as compared with those in other 
studies or in usual daily practice. Because PCI in the CLEAR 
study was required to be performed 7 days after diagnostic 
tion.1,3 Focusing on the modifiable factors, the various strat-
egies aimed at reducing periprocedural myocardial injuries 
have included many pharmacological interventions.2,3,5,6 In 
the end, cilostazol has the potential to reduce periprocedur-
al myonecrosis. First, cilostazol is a well-known antiplatelet 
agent that inhibits the platelet aggregation normally induced 
by collagen, 5ʼ-adenosine diphosphate, epinephrine, and ar-
achidonic acid.7,15-17 The beneficial antithrombotic and anti-
platelet effects of cilostazol as maintenance therapy follow-
ing PCI have already been proven through many trials.16,17 
However, cilostazol pretreatment in our study failed to dem-
onstrate any significant protective effects to reduce peripro-
cedural myonecrosis. Previously, there had been some efforts 
to reduce myonecrosis with further inhibition of platelets by 
glycoprotein IIb/IIIa inhibitors. However, further inhibition 
of platelet function by abciximab did not afford additional 
cardioprotection.6 Similarly, and despite the different mech-
anism of action of cilostazol relative to aspirin or clopido-
grel, additional use of cilostazol to conventional dual anti-
platelet therapy before PCI did not reduce the occurrence of 
periprocedural myonecrosis, suggesting that the intensified 
antiplatelet actions associated with the addition of cilostazol 
might not cause a reduction in cardiac enzyme level in-
creases after PCI.
From our CLEAR trial, we sought to evaluate the relation-
ship between clopidogrel resistance, which can be reduced 
by cilostazol, and the occurrence of periprocedural myone-
crosis. Aspirin resistance has been identified as one of the 
risk factors for postprocedural myocardial injuries, and clopi-
Table 6. Comparisons of Increases in Postprocedural Cardiac Enzyme and Follow-Up Clinical Outcomes Ac-
cording to Clopidogrel Resistance
Variable
Clopidogrel resistance 
(n=37)
Normal response 
(n=73)
p value
Any CK-MB elevation, n (%)   8 (22) 19 (26) 0.797
CK-MK elevation ≥3 times UNL, n (%) 2 (5) 4 (5) 1.000
CK-MK elevation ≥10 times UNL, n (%) 1 (3) 2 (3) 1.000
Any cTnI elevation, n (%) 14 (38) 26 (36) 0.826
cTnI elevation ≥3 times UNL, n (%)   5 (14) 14 (19) 0.765
cTnI elevation ≥10 times UNL, n (%) 3 (8)   7 (10) 0.870
6-month cumulative events
    Death, cardiac, n (%) 0 (0) 1 (1) 1.000
    MI, n (%) 1 (3) 0 (0) 0.177
    TLR, n (%) 2 (5) 1 (1) 0.298
    CVA, n (%) 1 (3) 0 (0) 0.177
    Death, MI, TLR, or CVA, n (%)   4 (11) 2 (3) 0.100
    Stent thrombosis, n (%) 1 (3) 1 (1) 0.670
Values are mean±SD or numbers (percentages). 
CK-MB, creatine kinase-MB; UNL, upper normal limit; cTnI, cardiac troponin I; MI, myocardial infarction; TLR, target-lesion revasculariza-
tion; CVA, cerebrovascular accidents.
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tor. Finally, the theoretical background for a 7-day duration 
of cilostazol pretreatment was not clearly established. In ad-
dition, there was no value regarding P2Y12 reaction units.
In conclusion, this randomized CLEAR trial failed to dem-
onstrate any cardioprotective effects of pretreatment with ci-
lostazol (200 mg/d for 7 days) on periprocedural myonecro-
sis in patients with stable angina undergoing elective PCI. 
Although cilostazol pretreatment could successfully reduce 
clopidogrel resistance in addition to inhibiting platelets, 
these were not translated into the reduction of periprocedur-
al myonecrosis. Eventually, some potential actions of cilo-
stazol pretreatment for the reduction of periprocedural myo-
necrosis might be less prominent than those of other well-
known protectors of the myocardium, such as statins with 
anti-inflammatory action or aspirin or clopidogrel with anti-
platelet function. However, for proper understanding of the 
mechanisms and the exact role of cilostazol, a double-blind, 
placebo-controlled, multi-center trial will be needed with a 
larger sample size. 
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